Evaluation of antimicrobial combinations against colistin-resistant carbapenemase (KPC)-producing Klebsiella pneumoniae

Journal of Chemotherapy

Volumn 27, Issue 6, 2015, Pages 348-352

  Maraki, S ^a   Papadakis, I S ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BLAKPC GENE; DRUG SCREENING; GENE; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; COMBINATION DRUG THERAPY; CROSS INFECTION; DRUG EFFECTS; ENZYMOLOGY; EPIDEMIOLOGY; EVALUATION STUDY; GREECE; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; METABOLISM; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GREECE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; POLYMERASE CHAIN REACTION;

EID: 84954064282     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947814Y.0000000218     Document Type: Article

References (29)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707.
2. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009;53(8):3365-70.
3. Navon-Venezia S, Leavitt A, Schwaber MJ, Rasheed JK, Srinivasan A, Patel JB, et al. First report on an hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother. 2009;53(2):818-20.
4. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother. 2009;64(2):348-52.
5. Rice LB, Carias LL, Hutton RA, Rudin SD, Endimiani A, Bonomo RA. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2008;52(9):3427-9.
6. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, et al. Controlling the spread of carbapenemaseproducing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect. 2010;16(2):102-11.
7. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32.
8. Qureshi ZA, Paterson DL, Potoski BA, KilaykoMC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108-13.
9. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322-8.
10. Naas T, Cuzon G, Villegas MV, Lartique MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase blaKPC gene. Antimicrob Agents Chemother. 2008;52(4):1257-63.
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard-ninth edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. p. M07-A9.
12. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation forMICs and zone diameters: version 3.1, valid from 2013-02-11. Basel, Switzerland: EUCAST. 2013.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 23rd informational supplement edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2013. p. M100-S23.
14. Lorien V, Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations. In: Lorien V, editor. Antibiotics in laboratory medicine, 4th edn. Baltimore: The Williams & Wilkins Co. 1996 p. 330-96.
15. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
16. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis. 2009;9(4):228-36.
17. Ellington MJ, Livermore DM, Pitt TL, Hall LM, Woodford N. Mutators among CTX-M b-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother. 2006;58(4):848-52.
18. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66(4):946-7.
19. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenemresistant enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58(2):654- 63.
20. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus rifampicin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57(8):3990-3.
21. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, et al. In vitro activities and post-antibiotic effect of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69(7):1856-65.
22. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005;56(1):128-32.
23. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol. 2010;48(10):3558-62.
24. Kádá r B, Kocsis B, Tó th Á, Damjanova I, Szá sz M, Kristó f K, et al. Synergistic antibiotic combinations for colistin resistant Klebsiella pneumoniae. Acta Microbiol Immunol Hung. 2013;60(2):201-9.
25. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2012; 56(6):3395-8.
26. Lee GC, Burgess DS. Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae. J Clin Med Res. 2013;5(2):97-100.
27. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37(3):244-7.
28. Yoon J, Urban C, Terzian C, Mariano N, Rahal J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampicin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004;48(3): 753-7.
29. Pankey GA, Ashcraft DS, Dornelles A. Comparison of 3 Etest methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2013;77(3):220-6.